# psoriasis - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 5409
- Completion tokens: 8563
- Reasoning tokens: 
- Total tokens: 13972
- API requests reported: 
- Elapsed seconds: 21.394
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The transcriptomic dataset comparing psoriatic lesional skin to normal control skin reveals a hallmark molecular profile dominated by **keratinocyte hyper-responsiveness, innate immune activation, aberrant epidermal differentiation, and local metabolic rewiring**. 

Rather than isolated gene changes, the data reflects a tightly coupled inflammatory loop:
* **Cytokine and Alarmin Amplification:** Massive upregulation of interleukin-36 family cytokines (`IL36A`, `IL36G`), along with `IL19` and `IL20`, indicates intense localized signaling downstream of IL-17/TNF pathways. This is accompanied by strong induction of alarmins and antimicrobial peptides (`DEFB4A`, `DEFB4B`, `DEFB103A/B`, `S100A12`, `S100A7`, `S100A8`, `PI3`), reflecting an overactive cutaneous innate defense system.
* **Epidermal Differentiation and Structural Remodeling:** Concurrently, genes encoding cornified envelope precursors (`SPRR2A/B/D/E/F/G`, `SPRR3`, `LCE3A`, `LCE3D`), keratinocyte stress markers (`KRT6A`), and gap junction proteins (`GJB2`, `GJB6`) are markedly elevated, capturing the characteristic epidermal hyperplasia, parakeratosis, and altered barrier function seen in psoriatic lesions.
* **Metabolic Alterations:** Enzymes such as `KYNU` (kynureninase) and `AKR1B10`/`AKR1B15` (aldo-keto reductases) show substantial induction, highlighting metabolic adaptation (tryptophan catabolism and lipid/retinoid metabolism) in response to chronic cutaneous inflammation.
* **Repression of Homeostatic Signals:** Key downregulated transcripts, such as the EGFR ligand betacellulin (`BTC`) and cytochrome P450 enzyme `CYP2W1`, signal a loss or negative feedback suppression of normal baseline epidermal homeostatic processes.

---

### 2. Core Biological Programs

```
+-----------------------------------------------------------------------------------+
|                            CORE BIOLOGICAL PROGRAMS                               |
+-----------------------------------------------------------------------------------+
| 1. IL-36 / IL-17 Epidermal Cytokine Cascade  (Upregulated; GO:0070555 / KEGG)     |
| 2. Antimicrobial & Alarmin Response         (Upregulated; GO:0019730)             |
| 3. Aberrant Cornification & Barrier Repair   (Upregulated; GO:0031424 / Reactome)  |
| 4. Tryptophan & Lipid Metabolic Rewiring     (Upregulated; KEGG: hsa00380)         |
| 5. Leukocyte Chemotaxis & Immune Influx      (Upregulated; GO:0030593)             |
+-----------------------------------------------------------------------------------+
```

#### Program 1: IL-36 and IL-17 Epithelial Amplification Cascade
* **Direction:** Upregulated
* **Supporting Genes:** `IL36A` ($\log_2\text{FC} = 11.37$), `IL36G` ($\log_2\text{FC} = 5.68$), `IL19` ($\log_2\text{FC} = 7.58$), `IL20` ($\log_2\text{FC} = 5.67$), `TNIP3` ($\log_2\text{FC} = 7.28$), `IL36RN` ($\log_2\text{FC} = 3.01$), `IRAK2` ($\log_2\text{FC} = 2.08$)
* **Standardized Pathway:** Reactome: *Interleukin-36 signaling* (R-HSA-9020524) / KEGG: *IL-17 signaling pathway* (hsa04657)
* **Biological Rationale:** `IL36A` and `IL36G` are key pro-inflammatory drivers expressed by keratinocytes that trigger downstream NF-$\kappa$B and AP-1 activation via `IRAK2`. `IL19` and `IL20` act downstream of IL-17A to promote keratinocyte proliferation. Upregulation of `TNIP3` and `IL36RN` reflects concurrent induction of negative feedback regulators in response to sustained inflammatory signaling.
* **Evidence & Limitations:** **Strong.** Supported by extremely high effect sizes and highly significant FDR values across multiple pathway components. *Limitation:* Transcript abundance alone does not confirm protein cleavage/activation (e.g., protease-mediated maturation of IL-36 cytokines).

#### Program 2: Cutaneous Antimicrobial Defense and Alarmin Response
* **Direction:** Upregulated
* **Supporting Genes:** `DEFB4A` ($\log_2\text{FC} = 11.18$), `DEFB4B` ($\log_2\text{FC} = 11.03$), `S100A12` ($\log_2\text{FC} = 8.33$), `S100A7A` ($\log_2\text{FC} = 9.83$), `S100A8` ($\log_2\text{FC} = 7.73$), `S100A7` ($\log_2\text{FC} = 7.09$), `DEFB103A` ($\log_2\text{FC} = 5.76$), `PI3` ($\log_2\text{FC} = 9.24$)
* **Standardized Pathway:** GO: Biological Process: *Antimicrobial humoral response* (GO:0019730)
* **Biological Rationale:** Epidermal keratinocytes produce antimicrobial peptides ($\beta$-defensins, S100 proteins, and peptidase inhibitors like peptidase inhibitor 3/elafin, `PI3`) in response to pro-inflammatory cytokines. These proteins act directly as microbicides and indirectly as chemoattractants/DAMPs, driving sustained innate immune activation.
* **Evidence & Limitations:** **Strong.** Represents some of the largest magnitude fold-changes in the entire dataset. *Limitation:* High sequence homology among defensin gene duplicates (`DEFB4A`/`DEFB4B`) can result in cross-hybridization or alignment ambiguity in bulk sequencing datasets.

#### Program 3: Aberrant Epidermal Cornification and Envelope Assembly
* **Direction:** Upregulated
* **Supporting Genes:** `SPRR2A` ($\log_2\text{FC} = 7.31$), `SPRR3` ($\log_2\text{FC} = 7.18$), `SPRR2B` ($\log_2\text{FC} = 6.38$), `SPRR2D` ($\log_2\text{FC} = 5.92$), `LCE3A` ($\log_2\text{FC} = 8.30$), `LCE3D` ($\log_2\text{FC} = 5.31$), `SERPINB4` ($\log_2\text{FC} = 9.12$), `SERPINB3` ($\log_2\text{FC} = 6.74$), `GJB2` ($\log_2\text{FC} = 4.42$), `KRT6A` ($\log_2\text{FC} = 4.30$)
* **Standardized Pathway:** GO: Biological Process: *Keratinization* (GO:0031424) / Reactome: *Formation of the cornified envelope* (R-HSA-6809371)
* **Biological Rationale:** Proliferation of suprabasal keratinocytes under inflammatory stress shifts the differentiation program toward alternative cornified envelope proteins (small proline-rich proteins `SPRR`, late cornified envelope proteins `LCE`) and stress keratins (`KRT6A`). Serine protease inhibitors (`SERPINB3/4`) are co-induced to protect against proteolytic barrier destruction.
* **Evidence & Limitations:** **Strong.** Coordinated induction across multiple distinct gene clusters located in the Epidermal Differentiation Complex (EDC) on chromosome 1q21. *Limitation:* Bulk transcript levels do not resolve spatial stratification across epidermal layers (basal vs. suprabasal).

#### Program 4: Metabolic Rewiring (Tryptophan & Lipid Catabolism)
* **Direction:** Upregulated
* **Supporting Genes:** `KYNU` ($\log_2\text{FC} = 4.42$), `AKR1B10` ($\log_2\text{FC} = 6.27$), `AKR1B15` ($\log_2\text{FC} = 5.23$), `FABP5` ($\log_2\text{FC} = 3.64$), `PLA2G4D` ($\log_2\text{FC} = 4.61$), `VNN3P` ($\log_2\text{FC} = 8.28$)
* **Standardized Pathway:** KEGG: *Tryptophan metabolism* (hsa00380) / *Arachidonic acid metabolism* (hsa00590)
* **Biological Rationale:** `KYNU` encodes kynureninase, a key enzyme in the tryptophan degradation pathway induced by IFN-$\gamma$ and TNF, producing immunosuppressive or inflammatory metabolites (e.g., 3-hydroxyanthranilic acid). `AKR1B10` and `AKR1B15` regulate lipid/retinoid metabolism and detoxification of lipid peroxidation products generated during oxidative stress in inflamed tissue.
* **Evidence & Limitations:** **Moderate to Strong.** Supported by consistent upregulation of metabolic enzymes. *Limitation:* Enzyme RNA levels do not directly prove altered metabolic flux or accumulation of downstream metabolites without metabolomic validation.

#### Program 5: Leukocyte Chemotaxis and Infiltrate Recruitment
* **Direction:** Upregulated
* **Supporting Genes:** `CXCL13` ($\log_2\text{FC} = 5.89$), `CXCR2` ($\log_2\text{FC} = 2.70$), `GPR15LG` ($\log_2\text{FC} = 5.52$), `IL26` ($\log_2\text{FC} = 4.36$), `CD274` ($\log_2\text{FC} = 3.44$)
* **Standardized Pathway:** GO: Biological Process: *Neutrophil chemotaxis* (GO:0030593) / *Leukocyte migration* (GO:0050900)
* **Biological Rationale:** `CXCL13` recruits follicular helper T cells and B cells, while `CXCR2` mediates neutrophil migration to the epidermis (forming Munro's microabscesses). `GPR15LG` (CCLI/colon and mucosal-associated epithelial chemokine) and `IL26` (a T-cell derived cytokine that complexes with DNA) recruit and activate immune cells in lesional skin.
* **Evidence & Limitations:** **Moderate.** High statistical significance of chemokine/receptor signals. *Limitation:* Transcript detection in bulk skin reflects a mixture of recruited infiltrating immune cells and resident skin cells; separating cell-type specific contributions requires single-cell resolution.

---

### 3. Key Genes and Interaction Modules

```
                        +----------------------------+
                        |  IL36A / IL36G / IL36RN    |
                        +--------------+-------------+
                                       | (Regulatory Signal)
                                       v
                        +----------------------------+
                        |  IRAK2 / TNIP3 / ZC3H12A   |
                        +--------------+-------------+
                                       |
             +-------------------------+-------------------------+
             | (Pathway Co-membership)                           | (Pathway Co-membership)
             v                                                   v
+--------------------------+                       +--------------------------+
| DEFB4A/B, S100A12, S100A8|                       | SPRR2A/3, LCE3A, KRT6A   |
| (Antimicrobial Module)   |                       | (Cornification Module)   |
+--------------------------+                       +--------------------------+
             |                                                   |
             +-------------------------+-------------------------+
                                       | (Co-expression in Lesion)
                                       v
                        +----------------------------+
                        |    KYNU / AKR1B10 / BTC    |
                        |   (Metabolic & Homeostatic)|
                        +----------------------------+
```

1. **`IL36A` ($\log_2\text{FC} = 11.37, \text{FDR} = 1.65 \times 10^{-98}$) & `IL36G` ($\log_2\text{FC} = 5.68, \text{FDR} = 1.43 \times 10^{-90}$):**
   * *Role:* Master upstream epithelial inflammatory cytokines.
   * *Interaction Nature:* **Regulatory Interaction** with downstream signaling adaptors (`IRAK2`) and negative feedback inhibitors (`TNIP3`, `IL36RN`). Direct physical binders to the IL-36 receptor complex (IL1RL2/IL1RAP).
2. **`DEFB4A` ($\log_2\text{FC} = 11.18$) / `DEFB4B` ($\log_2\text{FC} = 11.03$):**
   * *Role:* Key antimicrobial peptide effectors downstream of IL-17/IL-36 signaling.
   * *Interaction Nature:* **Co-expression** and **Pathway Co-membership** with `S100A7`/`S100A8`/`S100A12`. No direct physical binding between defensins and S100 proteins is required for function.
3. **`S100A12` ($\log_2\text{FC} = 8.33, \text{FDR} = 7.94 \times 10^{-97}$):**
   * *Role:* Endogenous alarmin that activates AGER (RAGE) signaling, driving neutrophil recruitment and amplification of inflammation.
   * *Interaction Nature:* **Regulatory Interaction** with pattern recognition receptors on immune cells; **Co-expression** with epidermal differentiation and defense modules.
4. **`KYNU` ($\log_2\text{FC} = 4.42, \text{FDR} = 2.00 \times 10^{-91}$):**
   * *Role:* Key node in tryptophan catabolism; converts L-kynurenine to 3-hydroxyanthranilic acid.
   * *Interaction Nature:* **Pathway Co-membership** within cytokine-induced metabolic adaptation modules; downstream transcriptional target of inflammatory cytokines (IFN-$\gamma$/TNF).
5. **`SPRR2A` ($\log_2\text{FC} = 7.31$) / `SPRR3` ($\log_2\text{FC} = 7.18$) / `LCE3A` ($\log_2\text{FC} = 8.30$):**
   * *Role:* Structural components of the cornified envelope assembled during stress-induced differentiation.
   * *Interaction Nature:* **Direct Physical Interaction** via transglutaminase-mediated covalent cross-linking during cornified envelope assembly; **Co-expression** within the EDC locus.
6. **`SERPINB3` ($\log_2\text{FC} = 6.74$) / `SERPINB4` ($\log_2\text{FC} = 9.12$):**
   * *Role:* Endogenous inhibitors of cysteine peptidases (cathepsins) and serine peptidases. Protect keratinocytes from protease-mediated damage.
   * *Interaction Nature:* **Direct Physical Interaction** (covalent suicide substrate complexing) with target peptidases; **Co-expression** with epidermal stress markers (`KRT6A`).
7. **`BTC` ($\log_2\text{FC} = -4.30, \text{FDR} = 1.78 \times 10^{-73}$):**
   * *Role:* Epidermal growth factor receptor ligand involved in normal basal keratinocyte growth and baseline skin homeostatic maintenance.
   * *Interaction Nature:* **Regulatory Interaction** (antagonistic expression trend relative to pro-inflammatory cytokines); ligand for EGFR/ERBB4 receptors.
8. **`TNIP3` ($\log_2\text{FC} = 7.27$) & `ZC3H12A` ($\log_2\text{FC} = 3.85$):**
   * *Role:* TNFAIP3-interacting protein 3 and Regnase-1 (RNase targeting inflammatory mRNAs), acting as anti-inflammatory feedback regulators.
   * *Interaction Nature:* **Regulatory Interaction** (post-transcriptional degradation of cytokine transcripts by ZC3H12A; inhibition of NF-$\kappa$B activation complexes by TNIP3).
9. **`AKR1B10` ($\log_2\text{FC} = 6.27, \text{FDR} = 2.35 \times 10^{-89}$):**
   * *Role:* Enzyme catalyzing reduction of retinals and toxic aldehydes, regulating retinoic acid synthesis and lipid detoxification in hyperproliferative keratinocytes.
   * *Interaction Nature:* **Co-expression** with stress-response genes; indirect metabolic regulation of nuclear receptor pathways (RAR/RXR).
10. **`CXCL13` ($\log_2\text{FC} = 5.89$) / `CXCR2` ($\log_2\text{FC} = 2.70$):**
    * *Role:* Chemokine-receptor signaling nodes orchestrating adaptive (CXCL13) and innate (CXCR2) cell influx into lesional tissue.
    * *Interaction Nature:* **Regulatory Interaction** via paracrine receptor binding (CXCR2 binds ELR+ CXC chemokines; CXCL13 binds CXCR5).

---

### 4. Validation Priorities

#### Priority 1: Functional impact of `BTC` loss in epidermal homeostasis
* **Category:** Mechanistic hypothesis
* **Prioritization Rationale:** `BTC` (Betacellulin) is among the most strongly downregulated transcripts ($\log_2\text{FC} = -4.29$). While upregulation of inflammatory cytokines is well characterized, the functional consequence of losing baseline homeostatic growth factor signaling via BTC on keratinocyte differentiation and barrier integrity remains understudied.
* **Input Dataset Evidence:** Severe downregulation in lesional skin ($P = 2.37 \times 10^{-76}$).
* **External Literature Evidence:** EGFR ligands maintain physiological skin architecture; loss of specific ligands can induce compensatory hyper-proliferation or sensitization to inflammatory cytokines.
* **Next Validation Step:** Recombinant BTC treatment or siRNA knockdown in primary human keratinocyte 3D skin models subjected to IL-17A/IL-36 stimuli, followed by barrier function and differentiation assays.
* **Evidence Status:** *Supported hypothesis*

#### Priority 2: Kynurenine pathway enzyme `KYNU` as a metabolic target
* **Category:** Therapeutic target
* **Prioritization Rationale:** `KYNU` shows robust upregulation ($\log_2\text{FC} = 4.42$). Inhibiting KYNU may modulate local immunosuppressive tryptophan metabolites and restore metabolic balance in lesional skin.
* **Input Dataset Evidence:** High statistically significant induction of `KYNU` ($P = 7.18 \times 10^{-95}$).
* **External Literature Evidence:** Tryptophan catabolism via the kynurenine pathway is implicated in inflammatory dermatoses and autoimmune regulation.
* **Next Validation Step:** Evaluate small-molecule KYNU enzymatic inhibitors in ex vivo psoriatic skin explant cultures, measuring downstream metabolites (3-HAA) and cytokine secretion.
* **Evidence Status:** *Exploratory hypothesis*

#### Priority 3: `S100A12` and `DEFB4A/B` serum/tissue protein concordance as disease activity markers
* **Category:** Biomarker
* **Prioritization Rationale:** `DEFB4A/B` and `S100A12` demonstrate large fold changes ($>8\text{--}11 \log_2\text{FC}$) and high statistical significance, making them strong candidates for tracking local tissue inflammation.
* **Input Dataset Evidence:** Top-ranking differentially expressed genes by fold change and FDR.
* **External Literature Evidence:** Serum human $\beta$-defensin 2 (hBD-2) and S100A12 correlate with PASI (Psoriasis Area and Severity Index) scores in clinical trials.
* **Next Validation Step:** Targeted ELISA or mass spectrometry validation in paired serum and biopsy samples from longitudinal patient cohorts undergoing biologic therapy.
* **Evidence Status:** *Established evidence*

#### Priority 4: Compensatory feedback failure of `IL36RN` and `TNIP3`
* **Category:** Mechanistic hypothesis
* **Prioritization Rationale:** Despite marked upregulation of inflammatory dampeners like `IL36RN` ($\log_2\text{FC} = 3.01$) and `TNIP3` ($\log_2\text{FC} = 7.28$), inflammation persists in lesional skin. Understanding why these endogenously induced inhibitors fail to resolve inflammation is critical.
* **Input Dataset Evidence:** Co-upregulation of pro-inflammatory cytokines (`IL36A`, `IL36G`) alongside their endogenous antagonists (`IL36RN`, `TNIP3`).
* **External Literature Evidence:** Loss-of-function mutations in `IL36RN` cause generalized pustular psoriasis (GPP), but in plaque psoriasis, relative protein stoichiometry or post-translational processing may alter the agonist-to-antagonist ratio.
* **Next Validation Step:** Stoichiometric protein quantification (Western blot / targeted proteomics) of IL-36 agonists versus IL-36RN in lesional vs. non-lesional tissue lysates.
* **Evidence Status:** *Supported hypothesis*

#### Priority 5: Cell-type deconvolution of immune vs. keratinocyte signaling
* **Category:** Confounding / composition check
* **Prioritization Rationale:** Bulk skin transcriptomics aggregates signals from multiple cell types (keratinocytes, fibroblasts, dendritic cells, neutrophils, T cells), potentially obscuring whether gene changes reflect cell-intrinsic upregulation or cellular composition shifts.
* **Input Dataset Evidence:** Concurrent upregulation of keratinocyte markers (`SPRR`, `LCE`) and leukocyte markers (`CXCR2`, `CXCL13`).
* **External Literature Evidence:** Psoriatic lesions exhibit significant immune cell infiltration and epidermal thickening.
* **Next Validation Step:** Perform single-cell RNA sequencing (scRNA-seq) or spatial transcriptomics on matching biopsies to map transcript expression to specific cell populations.
* **Evidence Status:** *Supported hypothesis*

---

### 5. Evidence Grounding

```
+---------------------------------------------------------------------------------------------------+
|                                  EVIDENCE MATRIX & INTEGRATION                                    |
+-------------------+--------------------+------------------------+---------------------------------+
| Biological Concept| Dataset Evidence   | Ontology / Pathway     | External / Literature Evidence  |
+-------------------+--------------------+------------------------+---------------------------------+
| IL-36 Cascade     | Direct (IL36A/G)   | Reactome R-HSA-9020524 | Independent (Genetics in GPP)   |
| Antimicrobial     | Direct (DEFB,S100) | GO:0019730             | Independent (Clinical Biomarker)|
| Cornification     | Direct (SPRR, LCE) | GO:0031424             | Independent (Histopathology)    |
| KYNU Metabolism   | Direct (KYNU)      | KEGG hsa00380          | Overlapping (IFN-g pathways)    |
| BTC Downregulation| Direct (BTC)       | Insufficient Pathway   | Independent (EGFR studies)      |
+-------------------+--------------------+------------------------+---------------------------------+
```

1. **IL-36 / IL-17 Amplification Axis:**
   * *Dataset Evidence:* Direct transcript enrichment of `IL36A`, `IL36G`, `IL19`, `IL20`.
   * *Pathway Evidence:* Canonical enrichment in Reactome *IL-36 signaling* and KEGG *IL-17 signaling*.
   * *External Evidence:* Monoclonal antibodies targeting IL-17A and IL-23 clear psoriatic plaques in clinical settings; human genetics links `IL36RN` loss-of-function to pustular skin inflammation.
   * *Relationship:* **Genuine Independent Evidence** bridging genomics, ontology, and clinical drug response.

2. **Antimicrobial and Cornification Markers:**
   * *Dataset Evidence:* Strong induction of `DEFB4A`, `S100A12`, `SPRR` family, `LCE` family.
   * *Pathway Evidence:* GO terms *Antimicrobial humoral response* and *Keratinization*.
   * *External Evidence:* Well-documented histological features of psoriasis (hyperkeratosis, parakeratosis, antimicrobial peptide accumulation).
   * *Relationship:* **Overlapping Sources** across transcriptomics and classical pathology describing the same physical cellular remodeling.

3. **Tryptophan Metabolism (`KYNU`):**
   * *Dataset Evidence:* Upregulation of `KYNU` ($\log_2\text{FC} = 4.42$).
   * *Pathway Evidence:* KEGG *Tryptophan metabolism*.
   * *External Evidence:* Literature reports elevated kynurenine pathway metabolites in inflamed skin and serum.
   * *Relationship:* **Supported Hypothesis**, though metabolic flux validation is currently absent from this transcriptomic dataset (*insufficient direct metabolic evidence*).

4. **Epidermal Downregulation (`BTC`):**
   * *Dataset Evidence:* Direct statistical evidence of `BTC` reduction ($\log_2\text{FC} = -4.30$).
   * *Pathway Evidence:* *Insufficient evidence* in standard pathway enrichment due to small gene set sizes of specific EGFR ligands.
   * *External Evidence:* EGFR signaling studies in skin model systems.
   * *Relationship:* **Exploratory Hypothesis** requiring functional validation.

---

### 6. Limitations and Alternative Explanations

1. **Cellular Composition Shift vs. Cell-Intrinsic Gene Regulation:**
   * *Complication:* Lesional skin exhibits marked epidermal hyperplasia and influx of neutrophils, T cells, and dendritic cells. Highly upregulated transcripts (e.g., `CXCR2`, `S100A12`, `CXCL13`) may simply reflect an increased proportion of infiltrating leukocytes rather than transcriptional induction per unit cell.
   * *Disambiguation:* Perform bioinformatic cell-type deconvolution (e.g., CIBERSORTx) or single-cell RNA-seq to differentiate cell composition changes from cell-intrinsic transcriptional changes.

2. **Sequence Homology and Read Misalignment in Gene Families:**
   * *Complication:* Highly similar multigene families located in close genomic proximity—such as `DEFB4A` / `DEFB4B`, `S100A7` / `S100A7A`, `AKR1B10` / `AKR1B15`, and `SPRR` family members—risk multi-mapping artifacts during standard RNA-seq read alignment.
   * *Disambiguation:* Re-align raw reads using strict unique-mapping criteria or validate specific transcripts using isoform/gene-specific quantitative RT-PCR with targeted primers.

3. **Pseudogene and Non-Coding RNA Annotation Artifacts:**
   * *Complication:* The top upregulated transcript is annotated as `VNN3P` ($\log_2\text{FC} = 8.28$), a pseudogene of the vanin vascular non-inflammatory molecule family. Other non-coding elements like `LINC01206`, `LINC03232`, and `WAKMAR1` are also differentially expressed. Pseudogene transcripts can represent transcript misassignment or non-functional read-through transcription.
   * *Disambiguation:* Confirm long non-coding RNA and pseudogene expression using strand-specific RT-qPCR and assess protein expression for the functional paraxonas/vanin enzymes (`VNN1`/`VNN2`).

4. **Confounding by Prior Treatment or Disease Subtype:**
   * *Complication:* The dataset does not explicitly specify patient treatment history (e.g., topical corticosteroids, systemic phototherapy, biologics) or disease severity (PASI score). Partial treatment exposure can suppress specific inflammatory axes while leaving structural cornification markers elevated.
   * *Disambiguation:* Stratify dataset samples by clinical metadata (treatment-naive vs. treated, mild vs. severe PASI) to control for systemic confounders.

5. **Association vs. Causation Ambiguity in Feedback Regulators:**
   * *Complication:* High expression of negative regulators (`TNIP3`, `IL36RN`, `ZC3H12A`) alongside pro-inflammatory cytokines (`IL36A`, `IL19`) could be misinterpreted as anti-inflammatory driving factors. In reality, these are likely reactive, secondary feedback responses triggered by primary inflammatory signaling.
   * *Disambiguation:* Perform time-course stimulation experiments in keratinocytes to define primary early-response genes versus secondary downstream feedback loops.
